Yasmin Post Marketing Surveillance
Information source: Bayer
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Contraception
Intervention: Yasmin (EE30/DRSP, BAY86-5131) (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer
Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Summary
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety
and efficacy in real practice.
Clinical Details
Official title: Yasmin Regulatory Post Marketing Surveillance
Study design: Cohort, Prospective
Primary outcome: Safety and efficacy evaluation in real practice
Secondary outcome: DemographyMedical History/Background Dose Concomitant medication Facility Diagnosis SAE/AE
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Women who need oral contraceptive
Exclusion Criteria:
- Patient who belongs to contraindication listed on the product label.
Locations and Contacts
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Many Locations, Korea, Republic of; Recruiting
Additional Information
Click here and search for drug information provided by the FDA Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product Click here to find results for studies related to marketed products
Starting date: March 2008
Ending date: January 2013
Last updated: October 14, 2009
|
